Sikander Ailawadhi

Ide-cel or Standard Regimens in Relapsed and Refractory Multiple Myeloma

Paula Rodríguez‐Otero, Sikander Ailawadhi, Bertrand Arnulf et al. · New England Journal of Medicine · 2023 · 627 citations · Full text

IAP antagonists induce anti-tumor immunity in multiple myeloma

Marta Chesi, Noweeda Mirza, Victoria M. Garbitt et al. · Nature Medicine · 2016 · 169 citations · Full text

Cancer Immunosurveillance, Immunology, Tumor Immunity +5

Treatment-Free Remission After Second-Line Nilotinib Treatment in Patients With Chronic Myeloid Leukemia in Chronic Phase

François-Xavier Mahon, Carla Boquimpani, Dong‐Wook Kim et al. · Annals of Internal Medicine · 2018 · 127 citations · Full text

Racial disparities in treatment patterns and outcomes among patients with multiple myeloma: a SEER-Medicare analysis

Sikander Ailawadhi, Kejal Parikh, Safiya Abouzaid et al. · Blood Advances · 2019 · 124 citations · Full text

Bortezomib, lenalidomide, and dexamethasone with or without elotuzumab in patients with untreated, high-risk multiple myeloma (SWOG-1211): primary analysis of a randomised, phase 2 trial

Saad Z. Usmani, Antje Hoering, Sikander Ailawadhi et al. · The Lancet Haematology · 2020 · 122 citations · Full text

Hematological Malignancy, Oncology, Hematology +6